Physicians’ Education Resource® (PER®), the
nation’s leading resource for oncology and hematology continuing medical
education (CME), will host its second annual Precision Medicine Through
Plasma: Using Liquid Biopsies in Contemporary Oncology Care workshop on
Saturday, Dec. 8 at the Convene in New York City. The workshop will be
chaired by Benjamin P. Levy, M.D., thoracic medical oncologist
and the clinical director of medical oncology, Johns Hopkins Sidney
Kimmel Cancer Center at Sibley Memorial Hospital, Associate Professor,
Johns Hopkins University School of Medicine.
“The introduction of liquid biopsies and plasma genotyping has
drastically altered the diagnostic algorithm for patients with multiple
solid tumor malignancies. These platforms not only have the ability to
accurately identify the genetic underpinnings of a tumor but may also
have utility to assess response to therapy in real time as well as
detect minimal residual disease (MRD) in patients who have undergone
curative intent therapy. This meeting is unique in brining together
disease-specific experts who will each highlight the role and promise of
liquid biopsies within their discipline,” Levy said.
The following key experts in lung, breast, and gastrointestinal
malignancies will provide an overview of the latest clinical data on
liquid biopsies, followed by detailed, real-world and practical
case-based discussions among a multidisciplinary faculty:
-
Ryan B. Corcoran, M.D., Ph.D., scientific director, Termer
Center for Targeted Therapy, director gastrointestinal cancer center
program, Massachusetts General Hospital Cancer Center
-
Massimo Cristofanilli, M.D., FACP, professor of medicine,
division of hematology and oncology, Northwestern University Feinberg
School of Medicine, associate director, translational research and
precision medicine, director, OncoSET precision medicine program,
Robert H. Laurie Comprehensive Cancer Center
-
Balazs Halmos, M.D., M.S., professor of clinical medicine,
director of thoracic/head and neck oncology, director, clinical cancer
genomic, Albert Einstein College of Medicine/Montefiore Medical Center
-
Bob T. Li, M.D., M.P.H., medical oncologist, thoracic oncology
and early drug development service, Memorial Sloan Kettering Cancer
Center
-
Geoffrey R. Oxnard, M.D., physician, Dana-Farber Cancer
Institute, associate professor of medicine, Harvard Medical School
-
Joseph A. Sparano, M.D., professor, department of medicine,
obstetrics, gynecology and women’s health, Albert Einstein College of
Medicine, associate director for clinical research, Albert Einstein
Cancer Center, , associate chairman for clinical research, department
of oncology, Montefiore Medical Center
-
John H. Strickler, M.D., assistant professor of medicine, Duke
University School of Medicine.
“It is very important for medical professionals to not only be aware of
the various actionable mutations, but also the methods to identify these
mutations,” said Phil Talamo, president of PER.® “We look forward to
offering this live CME workshop for the second year where attendees will
get the chance to gather, interact and learn more about providing better
patient care at each point along the disease continuum.”
This half-day live interactive educational CME/CE workshop will address
the rapidly evolving science and associated therapeutic developments
resulting from the emergence of novel testing strategies such as liquid
biopsies. Attendees will have the opportunity to increase their
confidence and competence in selecting emerging novel testing
strategies, such as liquid biopsies and plasma testing, as you strive to
provide the best care for your patients. Ample question-and-answer time
will also be provided for attendees to interact directly with the expert
faculty.
The activity offers AMA PRA Category 1 Credit.™ For registration and
more information, visit https://www.gotoper.com/conferences/pmlb/meetings/2nd-annual-precision-medicine-through-plasma-using-liquid-biopsies-in-contemporary-oncology-care.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care
through professional education and now furthers patient care and
treatment strategies on a wide variety of chronic illnesses and
diseases. In 2016, PER® initiated continuing medical
education (CME) programming in the cardiovascular and endocrinology
areas and continues to grow its therapeutic reach outside of oncology.
While continuing to expand into topics outside of oncology, PER®
remains the leading provider of live, online and print CME activities
related to oncology and hematology. The high-quality, evidence-based
activities feature leading distinguished experts who focus on the
application of practice-changing advances. In 2018, PER® will
develop and implement 21 historic annual legacy conferences in the
United States and Europe, along with many renowned online learning
formats. PER® is accredited by the Accreditation Council for
Continuing Medical Education and the California Board of Registered
Nursing. PER® is part of the Cranbury, New Jersey-based MJH
Associates Inc. family of businesses. Learn more at http://www.gotoper.com
and http://www.mjhassoc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005658/en/